AI MARKET SCANNING

Alumis Inc.

📅 Next Catalyst: Nov 12, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP -2.40%
MAX GAP RECORD -10.04%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ALMS
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 12, 2026 Earnings Release 2026-11-12 (UNDETERMINED) 🔮 UPCOMING 🔒
Aug 19, 2026 Earnings Release 2026-08-19 (BEFORE OPEN)
+2.41%
May 13, 2026 Earnings Release 2026-05-13 (AFTER CLOSE)
-2.17%
Mar 19, 2026 Earnings Release 2026-03-19 (AFTER CLOSE)
-2.13%
Nov 13, 2025 Earnings Release 2025-11-13 (AFTER CLOSE)
-10.04%
Aug 13, 2025 Earnings Release 2025-08-13 (AFTER CLOSE)
-5.88%
May 14, 2025 Earnings Release 2025-05-14 (AFTER CLOSE)
-0.44%
Mar 19, 2025 Earnings Release 2025-03-19 (AFTER CLOSE)
-2.06%

VOLATILITY & GAP BIAS

AVG GAP MOVE 3.2%
Bullish Gaps (2)
Bearish Gaps (6)
Neutral / Flat (1)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ALMS

EXECUTIONS2 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-10-30 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 941m +0.00%
••••-••-•• 🔒 LOCKED ••• x• $•••.•• → $•••.•• ••m +••.••%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗